Overview

* Sight Sciences ( SGHT ) Q2 revenue falls 8% yr/yr but beats analyst expectations, per LSEG data

* Operating expenses decreased 9% yr/yr

* Company raises full-year revenue guidance, indicating confidence in future performance

Outlook

* Sight Sciences ( SGHT ) raises full-year 2025 revenue guidance to $72.0 mln-$76.0 mln

* Company reaffirms 2025 adjusted operating expenses guidance at $101.0 mln-$105.0 mln

* Sight Sciences ( SGHT ) expects tariff costs to decrease to $1.0 mln-$1.5 mln in 2025

* Company anticipates 5%-10% revenue decline for full-year 2025 compared to 2024

Result Drivers

* MEDICARE RESTRICTIONS - Decline in Surgical Glaucoma revenue attributed to Medicare coverage restrictions on MIGS procedures with cataract surgery

* ORDERING ACCOUNTS - Increase in Surgical Glaucoma ordering accounts to an all-time high, partially offsetting revenue decline

* DRY EYE FOCUS - Decrease in Dry Eye revenue due to focus on achieving reimbursed market access for TearCare procedures

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $19.60 $18.20

Revenue mln mln (6

Analysts

)

Q2 Net -$11.90

Income mln

Q2 Gross 85.0%

Margin

Q2 Gross $16.60

Profit mln

Q2 $28.30

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Sight Sciences Inc ( SGHT ) is $4.00, about 8% above its August 6 closing price of $3.68

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)